1 1 Easterton Pharma Consulting Ltd 09010600 false 2023-05-01 2024-04-30 2024-04-30 The principal activity of the company is Other professional, scientific and technical activities not elsewhere classified Digita Accounts Production Advanced 6.30.9574.0 true 09010600 2023-05-01 2024-04-30 09010600 2024-04-30 09010600 bus:OrdinaryShareClass1 2024-04-30 09010600 core:CurrentFinancialInstruments 2024-04-30 09010600 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 09010600 core:OfficeEquipment 2024-04-30 09010600 bus:SmallEntities 2023-05-01 2024-04-30 09010600 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 09010600 bus:FilletedAccounts 2023-05-01 2024-04-30 09010600 bus:SmallCompaniesRegimeForAccounts 2023-05-01 2024-04-30 09010600 bus:RegisteredOffice 2023-05-01 2024-04-30 09010600 bus:Director1 2023-05-01 2024-04-30 09010600 bus:OrdinaryShareClass1 2023-05-01 2024-04-30 09010600 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 09010600 bus:Agent1 2023-05-01 2024-04-30 09010600 core:OfficeEquipment 2023-05-01 2024-04-30 09010600 countries:EnglandWales 2023-05-01 2024-04-30 09010600 2023-04-30 09010600 core:OfficeEquipment 2023-04-30 09010600 2022-05-01 2023-04-30 09010600 2023-04-30 09010600 bus:OrdinaryShareClass1 2023-04-30 09010600 core:CurrentFinancialInstruments 2023-04-30 09010600 core:CurrentFinancialInstruments core:WithinOneYear 2023-04-30 09010600 core:OfficeEquipment 2023-04-30 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 09010600

Easterton Pharma Consulting Ltd

Unaudited Filleted Financial Statements

for the Year Ended 30 April 2024

 

Easterton Pharma Consulting Ltd

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 7

 

Easterton Pharma Consulting Ltd

Company Information

Director

Dr Ennis Hilary Lee

Registered office

7A Kings Road
Easterton, Devizes
Devizes
SN10 4PU

Accountants

Imperium Tax and Accounting Ltd Unit 2F17, The Square
Basing View
Basingstoke
Hampshire
RG21 4EB

 

Easterton Pharma Consulting Ltd

(Registration number: 09010600)
Balance Sheet as at 30 April 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

5

1,789

3,905

Current assets

 

Debtors

6

-

6,632

Cash at bank and in hand

 

58,636

90,264

 

58,636

96,896

Creditors: Amounts falling due within one year

7

(15,812)

(27,668)

Net current assets

 

42,824

69,228

Net assets

 

44,613

73,133

Capital and reserves

 

Retained earnings

44,613

73,133

Shareholders' funds

 

44,613

73,133

For the financial year ending 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 23 January 2025
 

.........................................
Dr Ennis Hilary Lee
Director

 

Easterton Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
7A Kings Road
Easterton, Devizes
Devizes
SN10 4PU

These financial statements were authorised for issue by the director on 23 January 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Easterton Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

4

Profit before tax

Arrived at after charging/(crediting)

 

Easterton Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

2024
£

2023
£

Depreciation expense

2,116

1,474

 

Easterton Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

5

Tangible assets

Office equipment
£

Total
£

Cost or valuation

At 1 May 2023

8,464

8,464

At 30 April 2024

8,464

8,464

Depreciation

At 1 May 2023

4,559

4,559

Charge for the year

2,116

2,116

At 30 April 2024

6,675

6,675

Carrying amount

At 30 April 2024

1,789

1,789

At 30 April 2023

3,905

3,905

6

Debtors

Current

2024
£

2023
£

Trade debtors

-

5,417

Prepayments

-

1,215

 

-

6,632

7

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Taxation and social security

1,876

15,818

Accruals and deferred income

1,590

1,440

Other creditors

12,346

10,410

15,812

27,668

8

Share capital

Allotted, called up and fully paid shares

 

Easterton Pharma Consulting Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

2024

2023

No.

£

No.

£

Called up share capital of £1 each

1

1

1

1